All Resources

Professor Emanuele Bosi discusses a mandatory screening program for Type 1 diabetes and celiac disease in children and adolescents, launched in Italy in 2024.

Type 1 diabetes is underpinned by autoimmune activity against insulin-producing beta cells, as explained in this video.

Staging of autoimmune T1D allows us to track the progressive nature of the disease, from autoimmunity through to insulin dependence. 

A brief overview of the tools available for monitoring people with presymptomatic autoimmune type 1 diabetes, and the pros and cons for each method.

An overview of the screening methods for autoimmune type 1 diabetes (T1D).

Expert consensus on monitoring individuals with T1D islet autoantibodies: detection, monitoring frequency, and psychosocial support for managing autoimmune T1D.

T1D is an autoimmune disease whereby autoreactive T-cells drive progressive beta-cell damage and destruction, ultimately leading to insulin deficiency, dysglycemia, and hyperglycemia. 

Monitoring people with early-stage autoimmune T1D may reduce the risk of serious complications, such as DKA.

An overview of the stages of autoimmune type 1 diabetes, from the development of autoimmunity through to insulin dependence. 

Screening for autoimmune T1D involves testing for autoantibodies that are markers of destruction of insulin-producing beta cells.

Why and Who: an overview of the key considerations and decisions that inform screening people for islet autoantibodies.

The burden associated with a diagnosis of autoimmune T1D can be wide-ranging. This video describes the impact of diagnosis on an individual and their family.